Alzheon Announces Notice of Allowance for US Patent for its Lead Drug Candidate ALZ-801 in Clinical Development for Alzheimers Disease
![](/46/pdcnewsitem/02/89/32/q0W6oSfCNwW7SjF.gif)
Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and ageing, has announced that the United States Patent and Trademark Office (US PTO) has issued a notice of allowance for the U.S. Patent Application Number 11/871,639, entitled “Methods, Compounds, Compositions and Vehicles for Delivering 3-Amino-1-Propanesulfonic Acid.”
The allowed claims are directed to Alzheon’s lead therapeutic candidate ALZ-801, and protect the ALZ-801 compound, pharmaceutical compositions containing ALZ-801, as well as methods of treating Alzheimer’s disease using ALZ-801. Alzheon is currently advancing ALZ-801 into a confirmatory pivotal Phase 2/3 study in Alzheimer’s disease patients positive for ε4 allele of the apolipoprotein E.
Alzheon’s intellectual property represented in this patent is derived from the company’s acquisition of ALZ-801 and related assets in October 2013 as well as additional inventions by the company. To support its business and strategy, Alzheon has assembled and continues to build a strong intellectual property portfolio for the treatment of Alzheimer’s disease and other diseases of the central nervous system.
“We are very pleased to obtain this patent allowance for our lead clinical candidate. The allowance of this broad, foundational composition of matter patent further validates the innovative nature of our technology and the proprietary nature of our therapeutic approach and product candidate ALZ-801,” said Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon. “Alzheon is well positioned with a strong intellectual property estate as we execute on our growth-oriented strategy to advance Alzheon as a world-leading Alzheimer’s company.”
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance